SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001628280-20-000565
Filing Date
2020-01-27
Accepted
2020-01-27 17:13:33
Documents
5
Period of Report
2020-01-27
Items
Item 2.02: Results of Operations and Financial Condition
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K denalilaunch8-kjan27.htm 8-K 45140
2 EX-99.1 exhibit991denali8-k.htm EX-99.1 10001
3 EX-99.2 exhibit992denali8-k.htm EX-99.2 2078
4 EX-99.3 exhibit993denali8-k.htm EX-99.3 419761
5 denalitlogo011.jpg GRAPHIC 65449
  Complete submission text file 0001628280-20-000565.txt   565509
Mailing Address 161 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080
Business Address 161 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080 (650) 866-8548
Denali Therapeutics Inc. (Filer) CIK: 0001714899 (see all company filings)

IRS No.: 463872213 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38311 | Film No.: 20550610
SIC: 2836 Biological Products, (No Diagnostic Substances)